Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News SCYNEXIS Inc SCYX

Healthcare

SCYNEXIS, Inc. is a biotechnology company. It is pioneering medicine to overcome and prevent difficult-to-treat and drug-resistant infections. It develops antifungal platform fungerps, a novel class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have generally shown in vitro and in vivo activity against a range of human fungal pathogens,... see more

Add To Watchlist

Recent & Breaking News (NDAQ:SCYX)

SCYNEXIS, Inc. Announces Sale of Cyclophilin Inhibitor Assets to Cypralis Limited

GlobeNewswire July 13, 2016

SCYNEXIS, Inc. to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference

GlobeNewswire July 6, 2016

Momenta Pharmaceuticals Appoints Steven C. Gilman, Ph.D. to Board of Directors

GlobeNewswire June 23, 2016

SCYNEXIS Announces Pricing of $22.5 Million Public Offering of Common Stock and Warrants

GlobeNewswire June 21, 2016

SCYNEXIS Announces Launch of Public Offering of Common Stock and Warrants

GlobeNewswire June 20, 2016

SCYNEXIS Inc. Presents New Clinical and Non-Clinical Data Confirming the Potential of SCY-078 as a Novel Treatment for Life-threatening Fungal Infections

GlobeNewswire June 20, 2016

SCYNEXIS to Present Data from Lead Antifungal Drug Candidate SCY-078 at ASM Microbe 2016

GlobeNewswire June 10, 2016

11 Biggest Mid-Day Losers For Thursday

Benzinga.com June 9, 2016

Mid-Day Market Update: Restoration Hardware Falls Following Earnings Miss; Jaguar Animal Health Shares Jump

Benzinga.com June 9, 2016

SCYNEXIS, Inc. Announces Positive Results in its Proof-of-Concept Phase 2 Study of SCY-078, the First Member of a Novel Class of Glucan Synthase Inhibitors

GlobeNewswire June 8, 2016

SCYNEXIS, Inc. Receives Orphan Drug Designation for SCY-078 for the Treatment of Invasive Candida Infections

GlobeNewswire May 13, 2016

SCYNEXIS, Inc. Reports First Quarter 2016 Financial Results and Provides Company Update

GlobeNewswire May 9, 2016

SCYNEXIS Receives Designation as a Small and Medium Enterprise by the European Medicines Agency

GlobeNewswire April 19, 2016

SCYNEXIS Presents Data Supporting the Activity of its Lead Antifungal Drug Candidate SCY-078 Against Antifungal-resistant Candida Strains at the 13th ASM Conference on Candida and Candidiasis

GlobeNewswire April 15, 2016

SCYNEXIS, Inc. to Present at the 15th Annual Needham Healthcare Conference

GlobeNewswire April 6, 2016

SCYNEXIS to Present Data from Lead Antifungal Drug Candidate SCY-078 at 13th ASM Conference on Candida and Candidiasis

GlobeNewswire April 6, 2016

Keryx Biopharmaceuticals Announces New Appointments and Changes to its Board of Directors

GlobeNewswire April 1, 2016

SCYNEXIS, Inc. Reports Full Year 2015 Financial Results and Provides Company Update

GlobeNewswire March 7, 2016

SCYNEXIS, Inc. to Present at the Cowen and Company 36th Annual Health Care Conference

GlobeNewswire February 29, 2016

SCYNEXIS, Inc. to Present at Upcoming Investor Conferences

GlobeNewswire February 3, 2016